Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	10/13/2006 9:45:51 AM
	of 10280

Gaboxadol delayed by slow enrollment: >>8:01AM Merck announces that submission of a N.D.A for gaboxadol with the FDA will no longer occur in the 1Q07 (MRK) 42.76 : The co and H. Lundbeck A/S of Denmark announces that submission of a New Drug Application for gaboxadol with the FDA will no longer occur in the first quarter of 2007. The companies plan to submit the NDA in mid-2007. The delay in the N.D.A submission for gaboxadol, a novel investigational drug in Phase III development for the treatment of insomnia, results from slower than anticipated enrollment in ongoing Phase III trials. << From Briefing.com Another indication the sleep market is a bit crowded, even without Indiplon. Speaking of which, wasn't NBIX going to meet with the FDA about the extended release version this month, and announce the outcome? Why aren't NBIX options sporting higher IVs? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next